Alvocidib Biomarker-driven Phase 2 AML Study (Q64151617)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Alvocidib Biomarker-driven Phase 2 AML Study |
clinical trial |
Statements
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥40% (English)
0 references
14 March 2016
0 references
November 2020
0 references
79
0 references
18 year
0 references
65 year
0 references